LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

Search

BioCryst Pharmaceuticals Inc

Cerrado

SectorSalud

10.35 -0.48

Resumen

Variación precio

24h

Actual

Mínimo

10.28

Máximo

10.38

Métricas clave

By Trading Economics

Ingresos

27M

32K

Ventas

14M

146M

BPA

0

Margen de beneficio

0.022

Empleados

580

EBITDA

22M

21M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+58.63% upside

Dividendos

By Dow Jones

Próximas Ganancias

4 ago 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

473M

2.3B

Apertura anterior

10.83

Cierre anterior

10.35

Noticias sobre sentimiento de mercado

By Acuity

75%

25%

345 / 381 Clasificación en Healthcare

BioCryst Pharmaceuticals Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

15 jun 2025, 23:40 UTC

Adquisiciones, fusiones, absorciones

Santos Gets $18.72 Billion Takeover Offer From Adnoc-Led Consortium -- 2nd Update

15 jun 2025, 23:27 UTC

Adquisiciones, fusiones, absorciones

Santos Gets $18.72 Billion Takeover Offer From Adnoc-Led Consortium -- Update

15 jun 2025, 23:10 UTC

Adquisiciones, fusiones, absorciones

Santos Gets $18.72 Billion Takeover Offer From Adnoc-Led Consortium

13 jun 2025, 22:33 UTC

Adquisiciones, fusiones, absorciones

Millicom to Acquire Telefonica Ecuador for $380 Million

15 jun 2025, 23:50 UTC

Charlas de Mercado

Gold Edges Higher Amid Likely Safe-Haven Demand -- Market Talk

15 jun 2025, 23:47 UTC

Charlas de Mercado

Nikkei May Trade Rangebound Amid Uncertainty Over Middle East -- Market Talk

15 jun 2025, 23:41 UTC

Charlas de Mercado

Oil Rises Amid Middle East Tensions -- Market Talk

15 jun 2025, 23:33 UTC

Charlas de Mercado

China Most Affected by Any Disruption to Iran Crude Oil Exports -- Market Talk

15 jun 2025, 23:29 UTC

Charlas de Mercado

Oil Price Could Rise More This Week -- Market Talk

15 jun 2025, 23:27 UTC

Charlas de Mercado

Fed's Powell Likely to Emphasize Ongoing Policy Patience -- Market Talk

15 jun 2025, 23:27 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

15 jun 2025, 23:02 UTC

Charlas de Mercado

Global Energy Roundup: Market Talk

15 jun 2025, 23:02 UTC

Charlas de Mercado

Rising Middle East Tensions Could Be Passing Storm for World Economy -- Market Talk

15 jun 2025, 22:47 UTC

Adquisiciones, fusiones, absorciones

Santos Says Recommendation Requires Independent Expert Concluding Offer Is Fair, Reasonable

15 jun 2025, 22:47 UTC

Adquisiciones, fusiones, absorciones

Santos Intends to Recommend Shareholders Vote In Favor of Transaction If Binding Offer Made

15 jun 2025, 22:46 UTC

Adquisiciones, fusiones, absorciones

Santos Intends to Negotiate Terms of Process, Exclusivity Deed With XRG Consortium

15 jun 2025, 22:46 UTC

Adquisiciones, fusiones, absorciones

Santos to Give XRG Consortium Due Diligence Access

15 jun 2025, 22:45 UTC

Adquisiciones, fusiones, absorciones

Santos Says XRG Consortium Offer Is Final, Had Made Two Earlier Proposals

15 jun 2025, 22:45 UTC

Adquisiciones, fusiones, absorciones

Santos Says XRG Consortium Offering A$8.89/Share in Cash

15 jun 2025, 22:44 UTC

Adquisiciones, fusiones, absorciones

Santos Says XRG Consortium Includes Abu Dhabi Development Holding Co and Carlyle

15 jun 2025, 22:44 UTC

Adquisiciones, fusiones, absorciones

Santos Gets Takeover Offer From Consortium Led by Abu Dhabi's Adnoc

15 jun 2025, 22:31 UTC

Charlas de Mercado

Gold Price Can Push Toward New All-Time High -- Market Talk

14 jun 2025, 01:24 UTC

Adquisiciones, fusiones, absorciones

Nippon to Close U.S. Steel Deal After National-Security Pact With Trump -- 3rd Update

13 jun 2025, 23:50 UTC

Adquisiciones, fusiones, absorciones

Trump and Nippon Steel Reach National-Security Agreement on U.S. Steel Deal -- 2nd Update

13 jun 2025, 23:20 UTC

Adquisiciones, fusiones, absorciones

Trump and Nippon Steel Reach National-Security Agreement on U.S. Steel Deal -- Update

13 jun 2025, 23:09 UTC

Adquisiciones, fusiones, absorciones

Trump, Nippon Steel Reach National-Security Agreement on U.S. Steel Deal -- WSJ

13 jun 2025, 23:03 UTC

Adquisiciones, fusiones, absorciones

Trump, Nippon Steel Reach National-Security Agreement on U.S. Steel Deal --WSJ

13 jun 2025, 22:18 UTC

Adquisiciones, fusiones, absorciones

Millicom to Acquire Telefonica Ecuador for $380M

13 jun 2025, 22:04 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Better Data Facilitate Investments In Oil Patch -- Market Talk

13 jun 2025, 21:42 UTC

Adquisiciones, fusiones, absorciones

Anne Wojcicki Wins Bidding for 23andMe -- 2nd Update

Comparación entre iguales

Cambio de precio

BioCryst Pharmaceuticals Inc Esperado

Precio Objetivo

By TipRanks

58.63% repunte

Estimación a 12 meses

Media 16.45 USD  58.63%

Máximo 30 USD

Mínimo 11 USD

De acuerdo con 11 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para BioCryst Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

11 ratings

10

Comprar

1

Mantener

0

Vender

Sentimiento

By Acuity

345 / 381 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura bajista notoria

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.